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Summary:
the immaturity of the fetal immune system should allow transplanted foreign tissue to be accepted, avoiding the severe toxicities associated with BMT conditioning regimens. To date, in utero bone marrow transplantation (BMT) has had limited success, largely because of poor donor Moreover, in utero BMT should be feasible before the underlying disease can produce irreversible organ damage.
engraftment. The poor engraftment is probably the result of performing the procedure late in gestation
This is particularly important for BMT in the leukodystrophies, since only transplants done prior to the developafter significant fetal immunocompetence has developed and/or transplanting insufficient numbers of donor ment of significant neurologic damage appear to be efficacious. 1, 2 To date, however, in utero BMT has had limited hematopoietic stem cells for competing successfully with ongoing fetal hematopoiesis. To overcome these probsuccess, largely because of poor donor engraftment. 3, 4 This poor engraftment may be the result of performing the prolems, we performed in utero BMT on a fetus with globoid cell leukodystrophy during the first trimester of cedure late in gestation after significant immunocompetence has developed and/or transplanting insufficient numgestation using selected paternal bone marrow stem (CD34 + ) cells. CD34 selection allowed a substantially bers of donor hematopoietic stem cells (HSC) for competing successfully with ongoing host hematopoiesis. greater number of stem cells to be transplanted. Although the fetus died 7 weeks after the procedure
We performed in utero BMT on a fetus with globoid cell leukodystrophy early in gestation (the first trimester) using (during the 20th week of gestation), full donor engraftment was established. Moreover, the cause of selected parental bone marrow stem (CD34 + ) cells. Although the volume of marrow that can be transplanted death appeared to be overwhelming donor engraftment and leukostasis with paternal myeloid cells infiltrating into a first trimester fetus is limited, CD34 selection allowed transplantation of all the CD34 + marrow cells most tissues. The ability of in utero BMT to produce this degree of engraftment provides great promise for present in a full adult bone marrow harvest. Since CD34 is not expressed by immunocompetent T cells, this the use of this approach in the treatment of a variety of inherited disorders that can be diagnosed prenatally.
approach also depleted T cells responsible for the development of graft-versus-host disease (GVHD). Keywords: in utero transplantation; leukodystrophy; hematopoietic stem cells
Case report
Many inherited diseases that affect the lymphohematopo-
The family was referred to our institution after prenatal testietic system, such as severe-combined immunodeficiency ing at 10 weeks of gestation confirmed their fetus to be disease, ␤-thalassemia major, sickle cell disease, and variaffected with globoid cell leukodystrophy. The family had ous storage diseases, are potentially curable with postnatal had a previous child who had died before 1 year of age allogeneic bone marrow transplantation (BMT). 1 In utero with infantile globoid cell leukodystrophy. These patients BMT has the potential for avoiding many of the constraints follow a predictable course with the onset of symptoms of postnatal BMT for inherited diseases that can be diagbetween 3 and 6 months of age and death by 18 months. nosed prenatally. If performed early enough in gestation, Galactocerebrosidase activity from chorionic villus sampling (CVS) was virtually absent (Ͻ5% of normal), and DNA testing demonstrated homozygosity for the trophy. 5 The karyotype was that of a normal male. After genetic counseling, informed consent for in utero BMT commonly involved by GVHD (ie skin, intestine and bile ducts) had undergone significant autolysis. using the CellPro Ceprate SC as an investigational device for CD34 selection was given as approved by the Joint Committee for Clinical Investigation of the Johns Hopkins Discussion University and by the Food and Drug Administration (IND Previously, only limited myeloid engraftment has been seen No. 5790). The gestational age of the fetus at transplant after in utero BMT. 3, 4, 7, 8 Substantial lymphocyte was estimated at 13 and 3/7 weeks by dates and fetal engraftment, in the absence of myeloid engraftment, has crown-rump length.
been observed after in utero BMT for immunodefiThe father was used as bone marrow donor. A total of ciencies; 3,9 this is not surprising as isolated lymphocyte 2.43 × 10 10 nucleated bone marrow cells were harvested engraftment can be established after postnatal BMT for from the father's posterior iliac crest. The marrow was proimmunodeficiencies without the use of a conditioning regicessed on a COBE Spectra Cell Separator (Cobe BCT, men. However, a conditioning regimen is required to estabLakewood, CO, USA) to collect mononuclear cells, washed lish donor myeloid engraftment after postnatal BMT. in RPMI medium, and incubated with murine anti-CD34
The enhanced donor myeloid engraftment in our case antibody (CellPro (Bothell, WA, USA) 450 g/l for 25 min may be attributed to two distinct factors. Firstly, the in at room temperature). Automated cell washing was perforutero BMT was performed earlier in gestation than most med to remove excess antibody. The anti-CD34 antibodyprevious attempts, the majority of which were performed treated cells were processed through the CellPro Ceprate after 16 weeks. 3 The fetal immune system is immunotoler-SC Stem Cell Concentrator using a pre-established comant early in gestation, but becomes less so beyond the first puterized program to control the flow of cells through the trimester. 10, 11 In utero BMT during the first trimester is columns with washes to remove unbound residual cells.
possible because CVS may be performed as early as the The CD34
+ cells were collected after column agitation. 9th to 10th week of gestation, and the diagnosis established Under sterile conditions, 1.4 × 10 8 cells (91% CD34 + with within 1 week, in most inherited diseases. Secondly, 'posi-5% CD3
+ T cells by flow cytometry) were concentrated tive selection' technology for HSC using monoclonal antiinto 0.8 ml with 1.0% human serum albumin and infused body to CD34 concentrated greater numbers of human HSC under ultrasound guidance transabdominally through the into the small volume that can be transplanted in utero in mother into the peritoneal cavity of the fetus using a 22-the first trimester. The CD34 antigen is expressed on about gauge spinal needle. Thus, the fetus received about 5 × 10 9 1-2% of human bone marrow mononuclear cells, including CD34
+ cells/kg. This procedure was uncomplicated and all in vitro assayable hematopoietic progenitors and cliniobstetric ultrasound examination immediately and at 4 and cally transplantable HSC. 12, 13 We were able to transplant 14 h after BMT showed good fetal activity and a normal at least 100-fold more CD34 + cells/kg than previously possfetal heart rate.
ible. 3 Prior in utero transplants have generally utilized A follow-up ultrasound 1 week after BMT (at 14 weeks either fetal liver (with or without fetal thymus) or T cellgestation) and at 18 weeks gestation again showed good depleted parental marrow. 3 CD34 selection additionally fetal activity and heart rate as well as normal fetal growth.
provides some degree of T cell depletion since CD34 is not At 20 weeks of pregnancy, a routine obstetrical examinexpressed by immunocompetent T cells. Fetal liver cells ation revealed no fetal heart rate by Doppler and ultrasound may contain even fewer immunocompetent T cells. Howdocumented fetal death. The mother underwent induction ever, the use of CD34-selected paternal marrow affords of labor and a stillborn male was delivered approximately prompt accessibility and at least haploidentical HSC. 24 h later. The fetus was transferred on ice to Johns HopOverwhelming donor engraftment with leukostasis kins Hospital where an autopsy and engraftment studies appeared to be the most likely cause of fetal demise. We were performed.
transplanted at least 10-fold more CD34 + cells/kg than are Fetal death was estimated to have occurred about 1 week present in adults; this surplus of HSC may have overprior to delivery. Histologic examination revealed extensive whelmed the ability of the fetus to regulate hematopoiesis. extramedullary hematopoiesis (confirmed by immunohistoAlthough we cannot completely exclude a concomitant chemistry for myeloperoxidase), most prominent in the epielement of GVHD, this did not appear to be the cause of cardium, the serosa of the bowel, and the interstitium of the extensive hematologic infiltrates. GVHD does not the lungs and kidneys (Figure 1) . In multiple sites, there involve the epicardium, serosa of the bowel, or interstitium were hematopoietic cells in vessel walls and lumens with of the lungs and kidneys, and does not cause leukostasis. associated hemorrhage, consistent with leukostasis. There
The primary hematopoietic organ in a second trimester was no lymphoid infiltrate by histology or immunohistofetus, the liver, 6 was essentially completely replaced by chemistry for lymphoid markers (CD3 and CD20). DNAmyeloperoxidase-positive donor cells. Moreover, lymphorestriction fragment length polymorphism (RFLP) studies cytes could not be detected in the infiltrates. The ability of showed significant numbers of donor cells in most of the in utero BMT to produce this degree of engraftment proorgans assayed including the liver, spleen, thymus, and skin vides great promise for the use of this approach in the treat- (Figure 2 ). The primary hematopoietic organ in a second ment of inherited diseases that can be diagnosed prenatally. trimester fetus, the liver, was essentially completely
We plan to decrease the total number of CD34 + cells transreplaced by donor cells; hematopoiesis generally accounts planted in utero in future studies by about 10-fold; this for about half of all the cells in a second trimester liver. 
